Status: Ongoing
First registered on:
31/01/2017
Last updated on:
31/01/2017
1. Study identification
EU PAS Register NumberEUPAS17543
Official titleBurden of disease in patients with COPD and high blood eosinophil counts
Study title acronymHigh eosinophils and COPD
Study typeObservational study
Brief description of the studyPatients with COPD with high blood eosinophil counts (BEC) have an increased risk of exacerbations. This study aims to evaluate the role of high BEC measured during stable disease in the burden and costs of COPD in a broad real-life population of patients in the United Kingdom.
An observational historical follow-up study will be performed using medical records data for patients (aged ≥40 years) with COPD, from the Optimum Patient Care Research Database (OPCRD) and the Clinical Practice Research Datalink (CPRD)
The study has the following objectives:
1.To study the association between high BEC at the time of stable COPD (i.e., no recent exacerbation and stable treatment during the study period) and the prospective exacerbation rate in different subgroups of patients with COPD defined by treatment regimen and smoking habits and to study whether this association is also found in patients with good adherence to ICS
2. To study whether patients admitted to hospital for COPD exacerbation are more likely to be re-admitted if their pre-admission BEC is high
3. A. To estimate mean all-cause and COPD-related health care resource use (HRU) and associated costs in 4 subgroups of patients who are at risk of exacerbations (i.e. a history of ≥2 exacerbations or ≥1 exacerbation leading to hospitalisation in the past 12 months) while receiving treatment with triple therapy, where the 4 subgroups are defined by the presence or absence of high BEC and current smoking habits
B. to compare HRU and costs with those for the total population of patients with COPD who have BECs available
4.To study whether the presence of high BEC is associated with greater all-cause and COPD-related costs in the subsequent year and to study which other easily accessible characteristics drive future costs in patients with COPD.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupObservational and Pragmatic Research Institute Pte Ltd
Organisation/affiliationOPRI Pte Ltd
Details of (Primary) lead investigator
Title Professor
Last name Price
First name David
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed01/08/201601/08/2016
Start date of data collection15/09/201617/11/2016
Start date of data analysis03/10/201631/01/2017
Date of interim report, if expected16/12/2016
Date of final study report17/04/2017
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesAstraZeneca100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Price
First name David
Address line 15a Coles Lane
Address line 2Oakington
Address line 3
CityCambridge
PostcodeCB24 3BA
CountryUnited Kingdom
Phone number (incl. country code)441223967582
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Price
First name David
Address line 15a Coles Lane
Address line 2Oakington
Address line 3
CityCambridge
PostcodeCB24 3BA
CountryUnited Kingdom
Phone number (incl. country code)441223967582
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Not applicable (disease/epidemiology study)
7. Medical conditions to be studied
Medical condition(s)Yes
Chronic obstructive pulmonary disease
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects40000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Routine primary care electronic patient registry
11. Scope of the study
What is the scope of the study?
Disease epidemiology
Primary scope : Disease epidemiology
12. Main objective(s)
What is the main objective of the study?
To study the role of high blood eosinophil counts in the burden and costs of COPD in a broad real-life population of patients in the UK
Are there primary outcomes?Yes
COPD exacerbation rate for objective 1;
COPD-related short-term rehospitalisation for objective 2;
COPD-related HRU and costs for objectives 3&4;
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
Patients will be followed for 1 year after the date of blood eosinophil count measurement in this historical cohort study
15. Data analysis plan
Please provide a brief summary of the analysis method
Binomial regression will be performed to estimate the adjusted association between high BEC and COPD exacerbations for objective 1.
Cox-regression will be performed to estimate the adjusted association between high BEC and rehospitalisation for objective 2.
HRU and mean costs will be described for different subgroups of patients on triple therapy who are at risk of exacerbations for objective 3.
A one- or two-step generalized linear model with gamma distribution and log link will be used to perform regression analysis with total costs as the outcome variable for objective 4.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Available when the study ends
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
